Condensation of nicotinaldehydes with phenylethanones: A convenient synthesis and biological activities of chalcones by Bhimapaka, China Raju  et al.
 
 
Indian Journal of Chemistry 





Condensation of nicotinaldehydes with phenylethanones: A convenient synthesis 





, K Sai Teja
a






, A K Tiwari
b
, R S Prakasham
a
 & B China Raju*
a
 
a Department of Organic Synthesis & Process Chemistry 
and 
b Centre for Natural Products & Traditional Knowledge, 
CSIR-Indian Institute of Chemical Technology, Hyderabad 500 007, India 
E-mail: chinaraju@iict.res.in  
Received 3 September 2019; accepted (revised) 22 January 2020 
Claisen-Schmidt condensation of nicotinaldehydes 1a-e with various phenylethanones 2a-d in the presence of base at 
room temperature have provided chalcones 3a-t. All the synthesized compounds have been evaluated for their anti-
microbial, free-radical scavenging and α-glucosidase inhibitory activities. Compounds 3d and 3h have been identified as 
potent anti-fungal and moderate anti-bacterial agents. Compounds 3c, 3h, 3k-m and 3q have shown α-glucosidase inhibitory 
activity. 
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Chalcones
1
 are biologically active heterocyclic 
compounds and received considerable attention due to 

























2-Chloronicotinaldehydes are valuable compounds 
having chloro and formyl functional groups. As part of 
our research work on 2-chloronicotinaldehydes various 


























. The present 
research work has been designed to prepare 
nicotinaldehydes based chalcone derivatives and 
evaluation of their anti-microbial, DPPH, ABTS
.+
 free 
radical scavenging and α-glucosidase inhibitory 
activities. 
 
Results and Discussion 
The preparations of target chalcone compounds 3a-t 
have been depicted in Scheme I. The starting 
materials 2-chloronicotinaldehydes 1b-e have been 
prepared as per our earlier reported method
22
. The 
substituted acetophenones such as 1-(4-morpholin 
ophenyl)ethanone 2a, 1-(4-thiomorpholino 
phenyl)ethanone 2b, 1-(4-(4-phenylpiperazin-1-
yl)phenyl)ethanone 2c, and 1-(4-(4-benzylpiperazin-1-
yl)phenyl)ethanone 2d have been prepared by the 
reaction of 1-(4-fluorophenyl)ethanone with  
1-phenylpiperazine, 1-benzylpiperazine, morpholine 
and thiomorpholine in the presence of K2CO3 in DMF 
solvent at 110°C for 24 h. Claisen-Schmidt 
condensation of nicotinaldehydes 1a-e with 
phenylethanones 2a-d in the presence of 40% aq. 
sodium hydroxide in ethyl alcohol at room 
temperature afforded the target chalcone compounds 
3a-t. All the compounds are unknown and 
characterized by spectral data (Table I). 
The chalcones 3a-t have been evaluated for their 
biological activities such as anti-microbial23, DPPH, 
ABTS
.+
 free radical scavenging and α-glucosidase 
inhibitory
24
 and the results were discussed below. 
 
Anti-microbial activity 
All the compounds 3a-t were tested for their anti-
microbial activity against two Gram-positive 
organisms (Bacillus megaterium, Staphylococcus 
aureus) and two Gram-negative organisms 
(Salmonella typhi and Escherichia coli) by agar well 
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plate method and the results were presented in 
Table II. Two compounds 3d and 3h have shown 
significant anti-bacterial activity against tested gram 
positive (B. megaterium) and gram negative (S. typhi) 
bacterial strains when compared to standard drug. 
Compounds 3a-c, 3e-g, 3i-k and 3m-n have shown 
moderate anti-bacterial activity against B. 
megaterium. Only two compounds 3d and 3h have 
shown moderate anti-bacterial activity against S. 
aureus. Seven compounds 3c, 3g, 3k-l, 3p and 3r-t 
have shown moderate anti-bacterial activity against S. 
typhi. Ten compounds 3a-h, 3j and 3m have shown 
moderate anti-bacterial activity against E. coli. 
The structure activity relationships of the 
compounds revealed that the chalcone compound 3d 
(MIC 16, µg/mL) having thio-morpholine moiety 
without chloro substitution on pyridyl displayed 
moderate anti-microbial activity when compare to N-
phenyl 3a, N-benzyl 3b and morpholine 3c. The 
compound having thio-morpholine moiety 3h (MIC 
16, µg/mL) with chloro substitution on pyridyl 
displayed moderate anti-microbial activity when 
compared to N-phenyl 3i, N-benzyl 3j and 
morpholone 3k. Further, the presence of phenyl 3i-l, 
4-methylphenyl 3m-p and 4-fluorophenyl 3q-t on 
pyridyl reduced the activity. 
 Anti-fungal activities of target compounds 3a-t 
were tested against Candida albicans and fluconazole 
was used as standard drug (Table II). The compounds 





Table I — Preparation of nicotinaldehyde based chalcone derivatives 3a-t 
Entry Compd R X Y Yield a(%) 
1 3a H H N-C6H5 56 
2 3b H H N-CH2C6H5 63 
3 3c H H O 67 
4 3d H H S 67 
5 3e H Cl N-C6H5 61 
6 3f H Cl N-CH2C6H5 50 
7 3g H Cl O 56 
8 3h H Cl S 52 
9 3i C6H5 Cl N-C6H5 55 
10 3j C6H5 Cl N-CH2C6H5 53 
11 3k C6H5 Cl O 23 
12 3l C6H5 Cl S 69 
13 3m 4-CH3C6H5 Cl N-C6H5 62 
14 3n 4-CH3C6H5 Cl N-CH2C6H5 59 
15 3o 4-CH3C6H5 Cl O 45 
16 3p 4-CH3C6H5 Cl S 61 
17 3q 4-F-C6H5 Cl N-C6H5 42 
18 3r 4-F-C6H5 Cl N-CH2C6H5 33 
19 3s 4-F-C6H5 Cl O 31 
20 3t 4-F-C6H5 Cl S 25 
a Isolated yields 
 




shown potent anti-fungal activity in comparison with 
the standard drug (MIC 8 µg/mL). Compounds 3a, 3c, 
3g, 3l, 3p and 3t have shown moderate anti-fungal 
activity. The results of anti-microbial activity of the 
compounds 3a-t revealed that the thio-morpholine 
compounds 3d and 3h have shown both anti-bacterial 
and anti-fungal against when compared to 
morpholine, N-phenyl and N-benzyl. 
 
Free radicals scavenging activity 
The DPPH and ABTS
.+
 free radical scavenging 
activity (SC50 values) of nicotinaldehyde based 
chalcones (3a-d) and 2-chloronicotinaldehyde based 
chalcones (3e-t) are presented in Table III along with 
the standard drugs Ascorbic acid and Trolox. All 
these compounds have not shown promising free 
radical scavenging activity. However, compounds 3a 
and 3i-t have shown some DPPH free radical 
scavenging activity. However, compounds 3b-3h 
could not detect the DPPH free radical scavenging 
activity. Whereas, compounds 3a-t have shown some 
ABTS
.+
 free radical scavenging activity. 
 
α-Glucosidase inhibitory activity 
α-Glucosidase inhibitory activity of nicotinaldehyde 
based chalcones (3a-d) and 2-chloronicotinaldehyde 
based chalcones (3e-t) and their IC50 values presented 
in Table III along with the standard drug Acarbose. 
Total six compounds have shown α-glucosidase 
inhibitory activity in the present series of compounds 
among the synthesized 20 compounds. The compound 
having N-phenyl moiety on piperizine 3d (IC50 1.43 
µg/mL) has shown α-glucosidase inhibitory activity 
when compared to morpholine 3a, thio-morpholine 3b 
and N-benzyl 3d when compared to standard drug (IC50 
0.92 µg/mL). The thio-morpholine compound 3h 
displayed α-glucosidase inhibitory activity (IC50 2.86 
µg/mL) when compared to N-phenyl 3e, N-benzyl 3f, 
and morpholine 3g. The compounds morpholine (IC50 
1.39 µg/mL) and thio-morpholine (IC50 1.33 µg/mL) 
Table II — Anti-microbial activity profile of compounds 3a-t 
 Anti-bacterial Anti-fungal 
 Gram-positive Gram-negative 
Compd B. megaterium (MIC)* S. aureus  S. typhi (MIC)* E. coli  C. albicans (MIC)* 
3a 13 − − 11 13 
3b 14 − − 12 − 
3c 14 − 12 14 10 
3d 16 (16) 12 14 (32) 14 14 (8) 
3e 12 − − 11 − 
3f 12 − − 12 − 
3g 14 − 12 14 13 
3h 15 (16) 12 18 (16) 12 14 (8) 
3i 12 − − − − 
3j 12 − − 12 − 
3k 12 − 12 − − 
3l − − 13 − 11 
3m 14 − − 12 − 
3n 12 − − − − 
3o − − − − − 
3p − − 13 − 13 
3q − − − − − 
3r − − 13 − − 
3s − − 12 − − 
3t − − 13 − 13 
Control 0 0 0 0 0 
Streptomycin 27 (8) 20 20 (8) 22 − 
Fluconazole − − − − 15 (8) 
B. megaterium: Bacillus megaterium, S. aureus: Staphylococcus aureus, S. typhi: Salmonella typhi, E. coli: Escherichia coli, C. albicans: 
Candida albicans. 
*MIC (µg/mL): Minimum inhibitory concentration. 
The values represent the zone of inhibition in millimeter (mm) on agar plate against the represented microbial strains. The value in 
parentheses represents the MIC value (µg/mL). 
 




having phenyl substitution on pyridyl shown α-
glucosidase inhibitory activity when compared to 
phenyl 3i and N-benzyl 3j. Further, the N-phenyl 
compounds 3m, 3q (IC50 1.41, 1.74 µg/mL) having 
methyl and fluoro substitution on phenyl shown α-
glucosidase inhibitory activity when compared to N-
benzyl 3n, 3r, morpholine 3o, 3s and thio-morpholine 
3p, 3t. Overall, in the present series of compounds, the 
compounds 3d, 3h displayed anti-microbial activity 
and compounds 3c, 3h, 3k-m and 3q shown α-
glucosidase inhibitory activity. 
 
Experimental Section 
All the chemicals and reagents were purchased from 
Aldrich (Sigma-Aldrich, USA), AVRA Chemicals Pvt. 
Ltd (Hyderabad, India) and were used without further 
purification. Reactions were monitored by thin layer 
chromatography (TLC) on pre-coated silica gel 60 F254 
(mesh); spots were visualized under UV light. Melting 
points were determined on a Stuart melting point 
apparatus and are uncorrected. IR spectrum was 
recorded with a Thermo Nicolet Nexus 670 FT 
spectrometer. 
1
H NMR and 
13
C NMR spectra were 
recorded on Bruker Avance 300, 400 and 500 MHz 
spectrometers. Chemical shifts (δ) are quoted in parts 
per million and are referenced to tetramethylsilane 
(TMS) as internal standard. ESI-MS obtained on quarto 
micro spectrometer. 
 
General experimental procedure for the 
preparation of chalcones 3a-t 
Nicotinaldehyde 1a (1.0 mmol) and 1-(4-
morpholinophenyl)ethanone 2a ( 1.20 mmol) were 
dissolved in ethanol (2 mL). Aqueous sodium 
hydroxide solution (40%, 0.3 mL) was added 
gradually to the reaction mixture at RT and the 
contents were stirred until the starting materials 
disappeared (TLC). After completion of the reaction, 
the solvent was removed under reduced pressure. 
Cold water was added to the residue, neutralized with 
cold acetic acid and the reaction mixture was 
extracted with ethyl acetate (2 × 20 mL). The organic 
layer was washed with brine (2 × 20 mL) and the 
layers were separated. The organic layer was dried 
over anhydrous Na2SO4 and solvent was removed 
under reduced pressure. The crude product was 
purified by column chromatography (EtOAc/hexane) 
gave yellow color solid 3a. Similarly, compounds 3b-
t have been prepared by the reaction of 
nicotinaldehydes 1a-e with acetophenones 2b-d under 
optimized conditions. All the compounds are 
unknown and characterized by spectral data. 
Table III — DPPH, ABTS.+, α-glucosidase inhibitory activity profile of compounds 3a-t 
Compd DPPH  % Inhibition  
25 µg/mL (SC50 µg /mL) 
ABTS.+ % Inhibition  
20 µg /mL (SC50 µg /mL) 
α-GI % Inhibition  
20 µg/mL (IC50 µg /mL) 
3a 2.30 ± 0.17 44.96 ± 1.70  ND 
3b ND 8.80 ± 0.32 ND 
3c ND 6.99 ± 3.72 73.74 ± 0.49 (1.43) 
3d ND 8.72 ± 0.21 ND 
3e ND 15.71 ± 1.59 52.36 ± 0.85 
3f ND 16.84 ± 0.00 ND 
3g ND 9.70 ± 0.53 ND 
3h ND 9.55 ± 0.96 60.77 ± 1.57 (2.86) 
3i 34.58 ± 0.13 16.54 ± 1.06 57.78 ± 1.18 
3j 27.83 ± 1.96 2.86 ± 0.64 56.84 ± 0.24 
3k 21.75 ± 0.00 10.98 ± 0.00 74.53 ± 0.62 (1.39) 
3l 20.15 ± 0.08 3.61 ± 1.28 75.31 ± 0.49 (1.33) 
3m 18.99 ± 0.19 46.32 ± 0.43 74.61 ± 0.54 (1.41) 
3n 29.96 ± 0.40 8.05 ± 0.97 ND 
3o 11.71 ± 0.21 13.16 ± 0.53 ND 
3p 26.25 ± 0.86 8.12 ± 0.21 50.36 ± 0.62 
3q 52.46 ± 0.21 13.61 ± 0.53 67.61 ± 1.36 (1.74) 
3r  44.08 ± 0.00 7.07 ± 0.21 ND 
3s 36.12 ± 0.04 3.53 ± 0.11 ND 
3t 26.88 ± 0.08 6.77 ± 0.19 46.87 ± 0.21 
Ascorbic acid 91.04 ± 0.02 − − 
Trolox − 99.62 ± 0.32 − 
Acarbose − − 81.95 ± 0.41 (0.92) 
 





(pyridin-3-yl)prop-2-en-1-one, 3a: Yellow colored 
solid. m.p. 110-112°C. FT-IR (KBr): 3446, 2825, 





H NMR (500 MHz, CDCl3): δ 8.87 (s, 1H, 
aromatic), 8.61 (d, J = 3.7 Hz, 1H, aromatic), 8.03 (d, 
J = 8.9 Hz, 2H, aromatic), 7.94 (d, J = 7.9 Hz, 1H, 
aromatic), 7.77 (d, J = 15.7 Hz, 1H, CH), 7.63 (d, J = 
15.7 Hz, 1H, CH), 7.35 (dd, J = 7.8, 4.8 Hz, 1H, 
aromatic), 7.31 (t, J = 7.9 Hz, 2H, aromatic), 7.00-
6.96 (m, 4H, aromatic), 6.92 (t, J = 7.3 Hz, 1H, 
aromatic), 3.58-3.55 (m, 4H, 2CH2), 3.38-3.34 (m, 
4H, 2CH2); 
13
C NMR (126 MHz, CDCl3): δ 187.25, 
154.09, 150.83, 150.50, 150.47, 149.55, 149.51, 
139.22, 134.67, 130.80, 129.24, 127.91, 123.96, 
120.33, 116.32, 113.59, 49.02, 47.25; ESI-MS: m/z 
370 [M+H]
+
; HRMS (ESI): [M+H]
+
 m/z calcd for 
C24H24N3O = 370.1919, found = 370.1923. 
 
(E)-1-(4-(4-Benzylpiperazin-1-yl)phenyl)-3-(pyridin 
-3-yl)prop-2-en-1-one, 3b: Pale yellow solid. m.p. 181-
183°C. FT-IR (KBr): 3422, 2936, 2815, 1652, 1608, 




H NMR (500 MHz, 
CDCl3): δ 8.85 (d, J = 1.3 Hz, 1H, aromatic), 8.60 (d, 
J = 3.6 Hz, 1H, aromatic), 7.99 (d, J = 9.0 Hz, 2H, 
aromatic), 7.93 (d, J = 8.0 Hz, 1H, aromatic), 7.76 (d, 
J = 15.7 Hz, 1H, CH), 7.62 (d, J = 15.7 Hz, 1H, CH), 
7.35 (s, 2H, aromatic), 7.34 (t, J = 4.0 Hz, 3H, 
aromatic), 7.32-27 (m, 1H, aromatic), 6.90 (d, J = 9.0 
Hz, 2H, aromatic), 3.57 (s, 2H, CH2), 3.43-3.37 (m, 
4H, 2CH2), 2.63-2.57 (m, 4H, 2CH2);
 13
C NMR (126 
MHz, CDCl3): δ 187.20, 154.28, 150.62, 149.74, 
139.10, 137.68, 134.48, 131.0, 130.75, 129.12, 
128.31, 127.55, 127.24, 123.90, 123.67, 113.36, 





 m/z calcd for C25H26N3O = 
384.2076, found = 384.2073. 
 
(E)-1-(4-Morpholinophenyl)-3-(pyridin-3-yl)pro 
p-2-en-1-one, 3c: Pale yellow solid. m.p. 178-180°C. 
FT-IR (KBr): 2920, 2852, 1652, 1596, 1351, 1306, 




H NMR (500 MHz, 
CDCl3): δ 8.87 (s, 1H, aromatic), 8.62 (d, J = 3.9 Hz, 
1H, aromatic), 8.05-7.99 (m, 2H, aromatic), 7.94 (dd, J 
= 7.9, 1.7 Hz, 1H, aromatic), 7.77 (d, J = 15.7 Hz, 1H, 
CH), 7.63 (d, J = 15.7 Hz, 1H, CH), 7.36 (dd, J = 7.9, 
4.8 Hz, 1H, aromatic), 6.93 (d, J = 9.0 Hz, 2H, 
aromatic), 3.89-3.86 (m, 4H, 2CH2), 3.37-3.34 (m, 4H, 
2CH2);
 13
C NMR (126 MHz, CDCl3): δ 187.30, 154.30, 
150.62, 149.67, 139.33, 134.57, 131.04, 130.71, 
128.19, 123.77, 123.72, 113.32, 66.50, 47.33; ESI-MS: 
m/z [M+H]
+
 295; HRMS (ESI): [M+H]
+
 m/z calcd for 
C18H19N2O2 = 295.1447, found = 295.1453. 
 
(E)-3-(Pyridin-3-yl)-1-(4-thiomorpholinophenyl) 
prop-2-en-1-one, 3d: Pale yellow solid. m.p. 139-





H NMR (400 MHz, CDCl3): δ 8.86 
(d, J = 1.8 Hz, 1H, aromatic), 8.61 (dd, J = 4.8, 1.5 
Hz, 1H, aromatic), 8.04-7.97 (m, 2H, aromatic), 7.94 
(dt, J = 7.9, 1.8 Hz, 1H, aromatic), 7.77 (d, J = 15.7 
Hz, 1H, CH), 7.62 (d, J = 15.7 Hz, 1H, CH), 7.36 (dd, 
J = 7.9, 4.8 Hz, 1H, aromatic), 6.90-6.83 (m, 2H, 
aromatic), 3.86-3.81 (m, 4H, 2CH2), 2.74-2.70 (m, 
4H, 2CH2);
 13
C NMR (101 MHz, CDCl3): δ 187.05, 
152.98, 150.61, 149.68, 139.16, 134.51, 131.01, 
127.28, 123.78, 123.67, 113.64, 50.23, 25.79; ESI-
MS: m/z [M+H]+ 411. 
 
(E)-3-(2-Chloropyridin-3-yl)-1-(4-(4-phenylpiper 
azin-1-yl)phenyl)prop-2-en-1-one, 3e: Yellow 
coloured solid. m.p. 150-152°C. FT-IR (KBr): 2921, 
2852, 1594, 1453, 1393, 1221, 1191 cm−1; 1H NMR (500 
MHz, CDCl3): δ 8.41 (dd, J = 4.7, 1.8 Hz, 1H, 
aromatic), 8.05 (s, 1H, aromatic), 8.04-8.02 (m, 1H, 
aromatic), 8.01 (s, 1H, aromatic), 8.00 (s, 1H, aromatic), 
7.53 (d, J = 15.7 Hz, 1H, CH), 7.33 (d, J = 3.7 Hz, 1H, 
aromatic), 7.31 (d, J = 1.5 Hz, 1H, aromatic), 7.30 (d, J 
= 5.0 Hz, 1H, aromatic), 6.99 (d, J = 2.8 Hz, 2H, 
aromatic), 6.97 (d, J = 4.0 Hz, 2H, aromatic), 6.92 (t, J = 
7.3 Hz, 1H, aromatic), 3.57 (dd, J = 6.2, 4.1 Hz, 4H, 
2CH2), 3.37 (dd, J = 6.2, 4.1 Hz, 4H, 2CH2);
 13
C NMR 
(126 MHz, CDCl3): δ 187.29, 154.15, 151.64, 150.87, 
150.20, 150.12, 137.32, 136.09, 130.95, 130.61, 129.26, 
126.84, 122.73, 120.35, 116.33, 113.58, 49.04, 47.26; 
ESI-MS: m/z [M+H]
+ 
404; HRMS (ESI): [M+H]
+
 m/z 
calcd for C24H23N3OCl = 404.1530, found = 404.1533. 
(E)-1-(4-(4-Benzylpiperazin-1-yl)phenyl)-3-(2-
chloropyridin-3-yl)prop-2-en-1-one, 3f: Pale yellow 
solid. m.p. 146-148°C. FT-IR (KBr): 2923, 2844, 1658, 





(500 MHz, CDCl3): δ 8.40 (dd, J = 4.7, 1.7 Hz, 1H, 
aromatic), 8.03 (d, J = 2.1 Hz, 1H, aromatic), 8.02-7.99 
(m, 1H, aromatic), 7.97 (d, J = 9.0 Hz, 2H, aromatic), 
7.52 (d, J = 15.7 Hz, 1H, CH), 7.35 (s, 2H, aromatic), 
7.34 (d, J = 3.0 Hz, 2H, aromatic), 7.33-7.30 (m, 1H, 
aromatic), 7.30-7.27 (m, 1H, aromatic), 6.90 (d, J = 9.0 
Hz, 2H, aromatic), 3.58 (s, 2H, CH2), 3.42-3.39 (m, 
4H, 2CH2), 2.62-2.59 (m, 4H, 2CH2);
 13
C NMR (126 
MHz, CDCl3): δ 187.00, 154.25, 151.51, 149.99, 
149.19, 137.56, 136.99, 136.01, 130.82, 129.09, 
128.26, 127.20, 126.73, 122.68, 113.26, 62.85, 52.55, 




47.02; ESI-MS: m/z [M+H]
+
 418; HRMS (ESI): 
[M+H]
+




enyl)prop-2-en-1-one, 3g: Yellow solid. m.p. 151-
153°C. FT-IR (KBr): 2847, 1651, 1591, 1390, 1305, 




H NMR (400 MHz, CDCl3): δ 
8.41 (dd, J = 4.7, 1.8 Hz, 1H, aromatic), 8.05 (d, J = 
1.8 Hz, 1H, aromatic), 8.04-7.98 (m, 3H, aromatic), 
7.52 (d, J = 15.7 Hz, 1H, CH), 7.32 (dd, J = 7.9, 4.8 
Hz, 1H, aromatic), 6.92 (d, J = 9.0 Hz, 2H, aromatic), 
3.89-3.85 (m, 4H, 2CH2), 3.38-3.33 (m, 4H, 2CH2);
 
13
C NMR (101 MHz, CDCl3): δ 187.24, 154.33, 
151.54, 150.08, 137.29, 136.06, 130.82, 130.48, 
127.91, 126.68, 122.72, 113.26, 66.46, 47.27; ESI-
MASS: m/z [M+H]+ 329; HRMS (ESI): [M+H]+ m/z 
calcd for C18H18N2O2Cl =329.1057, found = 329.1062. 
 
(E)-3-(2-Chloropyridin-3-yl)-1-(4-thiomorpholin 
ophenyl)prop-2-en-1-one, 3h: Pale yellow solid. 
m.p. 110-112°C. FT-IR (KBr): 2911, 1650, 1590, 




H NMR (400 MHz, CDCl3): 
δ 8.41 (d, J = 2.4 Hz, 1H, aromatic), 8.04-7.97 (m, 
4H, aromatic), 7.53-7.49 (d, J = 6.9 Hz, 1H, 
aromatic), 7.33-7.30 (m, 1H, aromatic), 6.88-6.86 (d, 
J = 9.1 Hz, 2H), 3.84 (m, 4H, 2CH2), 2.72 (m, 4H, 
2CH2);
 13
C NMR (101 MHz, CDCl3): δ 186.99, 
152.98, 151.52, 150.04, 137.14, 136.07, 131.14, 







Pale yellow solid. m.p. 215-217°C. FT-IR (KBr): 





(500 MHz, CDCl3): δ 8.60 (d, J = 2.4 Hz, 1H, 
aromatic), 8.17 (d, J = 2.4 Hz, 1H, aromatic), 8.07 (d, 
J = 15.7 Hz, 1H, CH), 8.03 (d, J = 9.0 Hz, 2H, 
aromatic), 7.62 (d, J = 1.5 Hz, 1H, aromatic), 7.60 (s, 
1H, aromatic), 7.58 (s, 1H, aromatic), 7.53 (dd, J = 
8.2, 6.7 Hz, 2H, aromatic), 7.49-7.46 (m, 1H, 
aromatic), 7.31 (dd, J = 7.7, 6.4 Hz, 2H, aromatic), 
6.99-6.96 (m, 4H, aromatic), 6.92 (d, J = 7.3 Hz, 1H, 
aromatic), 3.59-3.55 (m, 4H, 2CH2), 3.38-3.35 (m, 
4H, 2CH2); 
13
C NMR (126 MHz, CDCl3): δ 187.27, 
154.21, 150.91, 150.34, 148.38, 157.37, 136.35, 
136.16, 134.49, 131.03, 130.33, 129.35, 129.30, 
128.80, 127.72, 127.20, 127.03, 120.38, 116.37, 





 m/z calcd for C30H27N3OCl = 




Pale yellow solid. m.p. 154-156°C. FT-IR (KBr): 





H NMR (500 MHz, CDCl3): δ 8.60 (d, J = 2.3 
Hz, 1H, aromatic), 8.16 (d, J = 2.3 Hz, 1H, aromatic), 
8.08 (dt, J = 15.7, 4.3 Hz, 2H, aromatic), 7.97 (dd, J = 
16.7, 5.5 Hz, 3H aromatic), 7.74 (d, J = 8.9 Hz, 1H, 
aromatic), 7.62-7.59 (m, 2H aromatic), 7.51 (d, J = 
8.2 Hz, 3H, aromatic), 7.36 (s, 2H, aromatic), 6.90 (d, 
J = 8.9 Hz, 2H aromatic), 6.71 (d, J = 8.7 Hz, 1H 
aromatic), 3.60 (s, 2H, CH2), 3.44-3.41 (m, 4H, 
2CH2), 2.63 (s, 4H, 2CH2); 
13
C NMR (110 MHz, 
CDCl3): δ 187.12, 154.29, 150.27, 148.27, 137.16, 
136.11, 130.93, 129.28, 129.20, 128.72, 128.35, 
127.35, 127.13, 113.37, 113.03, 62.89, 52.58, 47.04, 
46.79, 29.68; ESI-MS: m/z [M+H]
+
 494; HRMS 
(ESI): [M+H]
+
 m/z calcd for C31H29N3OCl = 
494.1999, found = 494.2000. 
 
(E)-3-(2-Chloro-5-phenylpyridin-3-yl)-1-(4-mo 
rpholinophenyl)prop-2-en-1-one, 3k: Pale yellow 
solid. m.p. 183-185°C. FT-IR (KBr): 2851, 1652, 




H NMR (400 MHz, CDCl3): δ 8.60 (d, J = 2.2 Hz, 
1H, aromatic), 8.17 (d, J = 2.3 Hz, 1H, aromatic), 
8.07 (d, J = 15.7 Hz, 1H, CH), 8.01 (d, J = 8.9 Hz, 
2H, aromatic), 7.60 (dd, J = 11.3, 9.5 Hz, 3H, 
aromatic), 7.53 (t, J = 7.5 Hz, 2H, aromatic), 7.47 (t, J 
= 7.3 Hz, 1H, aromatic), 6.92 (d, J = 8.9 Hz, 2H, 
aromatic), 3.89-3.85 (m, 4H, 2CH2), 3.37-3.34 (m, 
4H, 2CH2); 
13
C NMR (101 MHz, CDCl3): δ 187.28, 
154.40, 150.27, 148.32, 137.37, 136.29, 136.10, 
134.42, 130.89, 130.24, 129.28, 128.73, 128.01, 
127.13, 126.97, 113.32, 66.50, 47.36; ESI-MS: m/z 
[M+H]
+
 405; HRMS (ESI): [M+H]
+
 m/z calcd for 
C24H22N2O2Cl = 405.1370, found = 405.1372. 
 (E)-3-(2-Chloro-5-phenylpyridin-3-yl)-1-(4-thi 
omorpholinophenyl)prop-2-en-1-one, 3l: Pale 
yellow solid. m.p. 155-157°C. FT-IR (KBr): 2912, 





(400 MHz, CDCl3): δ 8.61 (d, J = 2.4 Hz, 1H, 
aromatic), 8.17 (d, J = 2.4 Hz, 1H, aromatic), 8.06 (d, 
J = 15.7 Hz, 1H, CH), 8.00 (d, J = 9.0 Hz, 2H, 
aromatic), 7.62-7.56 (m, 3H, aromatic), 7.53 (dd, J = 
10.1, 4.7 Hz, 2H, aromatic), 7.48-7.45 (m, 1H, 
aromatic), 6.86 (d, J = 9.0 Hz, 2H, aromatic), 3.85-
3.82 (m, 4H, 2CH2), 2.74-2.70 (m, 4H, 2CH2);
 
13C NMR (101 MHz, CDCl3): δ 187.14, 153.13, 
150.26, 148.33, 137.28, 136.36, 136.11, 134.53, 




131.31, 130.34, 129.34, 128.81, 127.47 -126.73, 





 m/z calcd for C24H22N2OSCl = 




Pale yellow solid. m.p. 126-128°C. FT-IR (KBr): 





H NMR (500 MHz, CDCl3): δ 8.59 (s, 1H, 
aromatic), 8.15 (s, 1H, aromatic), 8.02 (d, J = 8.3 Hz, 
2H, aromatic), 7.58 (d, J = 15.8 Hz, 1H, CH), 7.50 (d, 
J = 7.2 Hz, 2H, aromatic), 7.32 (s, 4H, aromatic), 6.95 
(dd, J = 20.2, 7.1 Hz, 6H, aromatic), 3.57 (s, 4H, 
2CH2), 3.36 (s, 4H, 2CH2), 2.44 (s, 3H, CH3); 
13
C NMR (126 MHz, CDCl3): δ 187.289, 154.14, 
150.86, 149.86, 148.20, 138.82, 137.42, 136.21, 
134.20, 133.17, 131.17, 130.17, 130.19, 130.00, 
129.25, 127.70, 126.95, 120.32, 116.31, 116.56, 





 m/z calcd for C31H29N3OCl = 




Pale yellow solid. m.p. 142-144°C. FT-IR (KBr): 





H NMR (500 MHz, CDCl3): δ 8.57 (d, J = 2.4 
Hz, 1H, aromatic), 8.14 (d, J = 2.4 Hz, 1H, aromatic), 
8.04 (t, J = 12.3 Hz, 1H, aromatic), 7.98 (d, J = 9.0 
Hz, 2H, aromatic), 7.57 (d, J = 15.7 Hz, 1H, 
aromatic), 7.50 (d, J = 8.1 Hz, 2H aromatic), 7.37-
7.34 (m, 4H, aromatic), 7.33-7.26 (m, 4H, aromatic), 
6.90 (d, J = 9.1 Hz, 2H, aromatic), 3.58 (s, 2H, CH2), 
3.44-3.39 (m, 4H, 2CH2), 2.63-2.57 (m, 4H, 2CH2), 
2.44 (s, 3H, CH3); 
13
C NMR (126 MHz, CDCl3): δ 
187.22, 154.36, 149.99, 148.19, 138.85, 137.53, 
137.24, 134.22, 133.21, 130.17, 130.98, 130.27, 
130.04, 129.24, 128.40, 127.37, 126.99, 113.42, 





 m/z calcd for C32H31N3OCl = 
508.2156, found = 508.2161. 
 
(E)-3-(2-Chloro-5-p-tolylpyridin-3-yl)-1-(4-mo 
rpholinophenyl)prop-2-en-1-one, 3o: Pale yellow 
solid. m.p. 159-161°C. FT-IR (KBr): 2850, 1652, 





(400 MHz, CDCl3): δ 8.58 (d, J = 2.2 Hz, 1H, 
aromatic), 8.15 (d, J = 2.1 Hz, 1H, aromatic), 8.06 (d, 
J = 15.8 Hz, 1H, CH), 8.01 (d, J = 8.9 Hz, 2H, 
aromatic), 7.58 (d, J = 15.7 Hz, 1H, CH), 7.50 (d, J = 
8.0 Hz, 2H, aromatic), 7.33 (d, J = 7.8 Hz, 2H, 
aromatic), 6.92 (d, J = 8.9 Hz, 2H, aromatic), 3.90-
3.85 (m, 4H, 2CH2), 3.38-3.33 (m, 4H, 2CH2), 2.43 (s, 
3H, CH3);
 13
C NMR (101 MHz, CDCl3): δ 187.18, 
154.31, 149.86, 148.12, 138.76, 137.35, 136.12, 
134.07, 113.03, 130.82, 130.05, 129.93, 127.90, 
126.86, 126.71, 113.23, 66.24, 47.24; ESI-MS: m/z 
[M+H]
+
 419; HRMS (ESI): [M+H]
+
 m/z calcd for 
C25H24N2O2Cl = 419.1526, found = 419.1528. 
 
(E)-3-(2-Chloro-5-p-tolylpyridin-3-yl)-1-(4-thi 
omorpholinophenyl)prop-2-en-1-one, 3p: Pale 
yellow solid. m.p. 103-105°C. FT-IR (KBr): 2920, 
1653, 1591, 1393, 1287, 1181 cm−1; 1H NMR (400 
MHz, CDCl3): δ 8.58 (d, J = 2.4 Hz, 1H, aromatic), 
8.14 (d, J = 2.4 Hz, 1H, aromatic), 8.05 (d, J = 15.7 
Hz, 1H, CH), 7.99 (d, J = 9.0 Hz, 2H, aromatic), 7.56 
(t, J = 9.3 Hz, 1H, aromatic), 7.50 (d, J = 8.1 Hz, 2H, 
aromatic), 7.32 (d, J = 7.9 Hz, 2H, aromatic), 6.86 (d, 
J = 9.0 Hz, 2H, aromatic), 3.83 (dd, J = 6.2, 3.8 Hz, 
4H, 2CH2), 2.73-2.70 (m, 4H, 2CH2); 
13
C NMR (101 
MHz, CDCl3): δ 187.17, 153.12, 149.98, 148.22, 
138.88, 137.39, 136.26, 134.25, 133.20, 131.28, 
130.24, 130.04, 127.02, 113.69, 50.31, 25.89, 21.25; 
ESI-MS: m/z [M+H]
+
 435; HRMS (ESI): [M+H]
+
 m/z 





one, 3q: Pale yellow solid. m.p. 168-170°C. FT-IR 





H NMR (500 MHz, CDCl3): δ 8.56 (s, 
1H, aromatic), 8.13 (s, 1H, aromatic), 8.04 (dd, J = 
18.6, 12.3 Hz, 3H, CH), 7.63-7.53 (m, 3H, aromatic), 
7.31 (t, J = 7.6 Hz, 2H, aromatic), 7.22 (t, J = 8.4 Hz, 
2H, aromatic), 7.00-6.89 (m, 5H, aromatic), 3.57 (s, 
4H, 2CH2), 3.36 (s, 4H, 2CH2);
 13
C NMR (126 MHz, 
CDCl3): δ 187.18, 154.18, 150.85, 150.34, 148.12, 
137.20, 135.36, 134.29, 132.27, 130.99, 130.36, 
129.26, 128.96, 128.89, 127.63, 127.12, 120.35, 
116.46, 116.32, 113.55, 49.03, 47.23; ESI-MS: m/z 
[M+H]
+
 498; HRMS (ESI): [M+H]
+
 m/z calcd for 




one, 3r: Pale yellow solid. m.p. 160-162°C. FT-IR 





H NMR (500 MHz, CDCl3): δ 8.55 (d, J = 2.4 Hz, 
1H, aromatic), 8.11 (d, J = 2.4 Hz, 1H, aromatic), 
8.04 (t, J = 12.3 Hz, 1H, aromatic), 8.00 - 7.97 (m, 
2H), 7.60 - 7.56 (m, 3H, aromatic), 7.36 - 7.33 (m, 




6H, aromatic), 7.22 - 7.20 (m, 1H, aromatic), 6.90 (t, 
J = 6.0 Hz, 2H, aromatic), 3.59 (s, 2H CH2), 3.43 - 
3.40 (m, 4H 2CH2), 2.62 (s, 4H 2CH2);
 13
C NMR (126 
MHz, CDCl3): δ 187.11, 154.29, 150.32, 148.08, 
137.07, 135.35, 134.28, 132.24, 130.95, 130.38, 
129.28, 128.95, 128.39, 127.44, 127.29, 116.44, 






1-(4-morpholinophenyl)prop-2-en-1-one, 3s: Pale 
yellow solid. m.p. 192-194°C. FT-IR (KBr): 3019, 





(400 MHz, CDCl3): δ 8.56 (d, J = 2.4 Hz, 1H, 
aromatic), 8.12 (d, J = 2.4 Hz, 1H, aromatic), 8.06 (d, 
J = 15.8 Hz, 1H, CH), 8.03-7.99 (m, 2H, aromatic), 
7.60-7.56 (m, 3H, aromatic), 7.22 (t, J = 8.6 Hz, 2H, 
aromatic), 6.92 (d, J = 9.0 Hz, 2H, aromatic), 3.89-
3.86 (m, 4H, 2CH2), 3.38-3.33 (m, 4H, 2CH2);
 
13
C NMR (101 MHz, CDCl3): δ 187.19, 164.43, 
161.95, 154.39, 150.28, 148.10, 137.22, 135.32, 
134.25, 130.89, 128.94, 128.85, 126.99, 116.44, 
116.23, 113.28, 66.48, 47.29; ESI-MS: m/z [M+H]
+
 
423; HRMS (ESI): [M+H]
+
 m/z calcd for 




Pale yellow solid. m.p. 115-117°C. FT-IR (KBr): 





H NMR (400 MHz, CDCl3): δ 8.56 (s, 
1H, aromatic), 8.12 (s, 1H, aromatic), 8.05 (d, J = 
15.7 Hz, 1H, CH), 7.99 (d, J = 8.5 Hz, 2H, aromatic), 
7.58 (dd, J = 8.7, 5.9 Hz, 3H, aromatic), 7.22 (t, J = 
8.4 Hz, 2H, aromatic), 6.86 (d, J = 8.6 Hz, 2H, 
aromatic), 3.85-3.82 (m, 4H, 2CH2), 2.72 (d, J = 4.2 
Hz, 4H, 2CH2);
 13
C NMR (101 MHz, CDCl3): δ 
187.03, 153.09, 150.33, 148.15, 137.15, 135.39, 
134.39, 132.27, 131.32, 130.37, 129.04, 128.96, 
127.15, 116.53, 116.32, 113.74, 38.85, 24.88; ESI-
MS: m/z [M+H]
+
 439; HRMS (ESI): [M+H]
+
 m/z 
calcd for C24H21N2OSClF = 439.1047, found = 
439.1044. 
 
Anti-bacterial activity  
The anti-bacterial activities of prepared compounds 
were evaluated against two Gram-positive (Bacillus 
megaterium, Staphylococcus aureus) and two Gram-
negative organisms (Salmonella typhi and 
Escherichia coli) by agar well plate method by using 
streptomycin as standard. The anti-fungal activities of 
prepared compounds were evaluated against yeast 
(Candida albicans) and fluconazole was used as 
standard drug. 
 
Zone of inhibition plate tests 
Well plate method is followed for both the anti-
bacterial and anti-fungal activities for measuring the 
zone of inhibitions. For anti-bacterial activity test 
strains used Gram positive and Gram negative in 
nutrient agar. For anti-fungal studies test strains used 
yeast and the medium used is potato dextrose agar. The 
synthesized compounds were used for activity studies 
and the concentration of each compound is 1.0 mg/mL 
along with standard and control. The media, petri 
dishes were autoclaved at 121 ºC for 15 min. After 
sterilization the plates were poured with appropriate 
medium left over for 30 min for solidification, later the 
plates were inoculated with 60 µl of test inoculum 
using sterile cotton swabs. An 8 mm width size wells 
were made with sterile cork borer and in each well 
exactly 100 µl of sample were loaded. Control and 
standard also placed in separate wells. The plates were 
initially incubated for 20-30 min at 4 ºC to allow the 
compounds to diffuse into the agar, and then 
subsequently incubated for 24 h at 37 ºC for bacteria 
and 48 h at 28 ºC for fungi. Zone diameters were 
expressed in mm using calibrated scale. Experiment 
was triplicate to minimize the deviations. 
 
Determination of MIC 
Minimum inhibition concentration (MIC) is the 
lowest concentration of an anti-microbial agent that 
will inhibit the visible growth of a microorganism. 
The MIC was determined using the tube dilution 
method. The compounds were dissolved in dimethyl 
sulfoxide (DMSO) at concentration of 0.500 mg /mL 
(stock solution). The compounds having better anti-
microbial activity were selected for the MIC 
(minimum inhibitory concentration) studies against all 
above microbial strains. The concentrations of test 
samples were serially diluted from 500 to 1.9µg/mL 
and one tube without drug serves as control. All the 
tubes were inoculated with 1 mL of respective 
cultures having an OD of 0.2 (~ McFarland standard) 
and the tubes were incubated at 37 ºC for 16 h. The 
turbidity of each tube is measured with respect to 
control tube. MIC values are defined as the lowest 
concentration of compound at which growth is 
completely inhibited. 
 
DPPH free radical scavenging assay 
Assay for the scavenging of stable free radical 1,1-
diphenyl-2-picrylhydrazyl (DPPH) was done. Briefly, 




in a 96-well micro plate, 25 µL of test sample 
dissolved in DMSO (1 mg/mL), 100 µL of 0.1 M tris-
HCl buffer (pH 7.4) and 125 µL of 0.5 mM DPPH 
solution dissolved in absolute ethyl alcohol were 
added. The reaction mixture was shaken well and 
incubated in dark for 30 min and read at 517 nm 
spectrophotometrically (Spectra Max plus 384, 
Molecular Devices Corporation, Sunnyvale, CA, 
USA). Percentage of DPPH scavenging was 
calculated as (1-B/ A) × 100 where A represents 
absorbance of control without test samples, and B 




 free radical scavenging assay  
 Scavenging of the ABTS.+ [2,2'-azino-bis(3-
ethylbenzothiazoline-6-sulphonic acid)] cation was 
performed as described by Walker and Everette with 
suitable modifications9. Briefly, 100 mL stock 
solution of ABTS
.+
 (0.5 mM) was prepared by 
addition of 1 mL potassium persulfate (6.89 mM PBS, 
pH 8.0). The mixture was stored in the dark for 16 h. 
Test compounds were dissolved in DMSO (5mg/mL). 
Primary screening was done by mixing 10 µL of test 
compounds in 100 µL of methanol followed by 190 
µL of ABTS
.+ 
in a 96-well microplate. Absorbance of 
decolorized ABTS
.+
 was measured at 734 nm after 15 
min incubation in the dark on a BioTeksynergy4 
multi-mode microplate reader. For each test sample a 
separate blank sample (devoid of ABTS
+
) was used 
for background subtraction. The percentage of 
ABTS
.+
 scavenging was calculated applying 
following formula: 
 
%ABTS.+ scavenging = [(Absorbance control− 
Absorbance test) / Absorbancecontrol×100] 
 
Various serial dilutions of active compounds were 
prepared and tested for determination of SC50 values. 
Suitable regression analysis was applied for 
calculation of SC50. 
 
α-Glucosidase inhibitory assay 
α-Glucosidase inhibitory activity was determined as 
per our earlier reported method
9
. Rat intestinal acetone 
powder in normal saline (100:1; w/v) was sonicated 
properly and the supernatant was used as a source of 
crude intestinal α-glucosidase after centrifugation. In 
brief, 10 µL of test samples (5 mg/mL DMSO solution) 
were reconstituted in 100 µL of 100 mM-phosphate 
buffer (pH 6.8) in 96-well microplate and incubated 
with 50 µL of crude intestinal α-glucosidase for 5 min 
before 50 µL substrate (5 mM, p-nitrophenyl-α-D-
glucopyranoside prepared in same buffer) was added. 
Release of p-nitrophenol was measured after 15 
minutes incubation at 405 nm spectrophotometrically 
(Spectra Maxplus 384), Molecular Devices 
Corporation, Sunnyvale, CA, USA) 5 min after 
incubation with substrate. Individual blanks for test 
samples were prepared to correct background 
absorbance where substrate was replaced with 50 µL of 
buffer. Control sample contained 10 µL DMSO in 
place of test samples. Percentage of enzyme inhibition 
was calculated as (1-B/A) x 100 where [A] represents 
absorbance of control without test samples, and [B] 
represents absorbance in the presence of test samples. 
 
Conclusion 
In conclusion, target compounds chalcones 3a-t 
has been prepared by the reaction of nicotinaldehydes 
1a-e with phenylethanones 2a-d in the presence of 
base at RT. The compounds were evaluated for their 
anti-microbial, free-radical scavenging and α-
glucosidase inhibitory activities. Compounds 3d and 
3h have been identified as potent anti-fungal agents. 
Compounds 3c, 3h, 3k-m and 3q have shown α-
glucosidase inhibitory activity. 
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